Table 1.
Comparison of the efficacy profiles (% achievement) of nilotinib,13 dasatinib,19 and bosutinib45 in the 3 registration phase 3 studies compared with imatinib
Nil(300) indicates nilotinib 300 mg; IM, imatinib; DAS, dasatinib; and BOS, bosutinib.
*Median follow-up was 36 months.
†Median follow-up was 24 months.
‡Median follow-up was 18 months.
